40 results about "Diabetic angiopathy" patented technology

The invention discloses a preparation method and use of skunk bush extract morroniside which consists of, extracting the Cornel medicinal material with ethanol, decompression concentration, concentration alcohol depositing, subjecting the supernatant fluid to column chromatography with macroporous absorption resin or activated charcoal, removing the impurity substance, gradient ethanol elution, decompressing, concentrating and drying the eluent, and reversed phase silica gel segregation. The invention also discloses its use in preparation of drug for preventing and treating diabetic nephropathy.

The invention relates to pharmaceutical composition containing GKAs (glucokinase activators) and B vitamins. The pharmaceutical composition is prepared from a therapeutic effective dose of one of GKAs as well as medicinal precursors, active metabolites or GKA salts, one or more of a therapeutic effective dose of the B vitamins and pharmaceutically acceptable carriers, wherein the GKAs mainly comprise TTP399, HMS5552, PF-04937319, LY2608204, PF-04991532 and GKM-001; the content of the B vitamins is 0.01-50 mg and adopt folic acid compounds as the first choice. The invention further relates to an application of the composition in preparation of drugs for treating diabetes mellitus and preventing or delaying complications of diabetic angiopathy.

The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and / or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.

The invention provides a dogwood extraction and its preparation method and use thereof, wherein the preparation consists of extracting dogwood with alcohol, depression concentrating the raffinate to a finite density, collecting the deposition, decompressing and drying, obtaining extract A, passing through macroscopic adsorption resin column, removing foreign substance through washing, ethanol elution, collecting the eluent, decompressing and drying, obtaining extract B, mixing extract A and B homogeneously, thus obtaining the dogwood extract. The invention discloses its novel pharmaceutical use in preparing medicament for prevention and treatment of diabetic blood vessel pathological changes and for reducing blood sugar.

The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and / or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.

The invention relates to a pharmaceutical composition containing SGLT2 (sodium-glucose type 2 transporter) inhibitors and group B vitamins. The pharmaceutical composition consists of SGLT2 inhibitors in therapeutically effective amount and one of medicinal precursors, active metabolites or salts thereof, one or more in group B vitamins in therapeutically effective amount, and pharmaceutically acceptable carriers, wherein the SGLT2 inhibitors mainly comprise dapagliflozin, remogliflozin and sergliflozin and have the content of 2.5-500mg, and the content of the group B vitamins is 0.01-50mg. The invention also relates to application of the composition in preparation of medicines for treating diabetes. The medicine prepared by the pharmaceutical composition provided by the invention has the beneficial effect of obviously preventing or delaying complication of diabetic angiopathies on the basis of effectively reducing blood sugar. In addition, the pharmaceutical composition can be conveniently taken by a patient, and the compliance is improved.

The invention provides berberine and panax notoginseng saponins and use of a composition using berberine and panax notoginseng saponins as effective components in preparing medicines for preventing and treating diabetes mellitus and complications thereof. The complications of diabetes mellitus are selected from diabetic cardiac abnormalities, diabetic renal lesions, diabetic retinopathy, diabetic peripheral neuropathy and diabetic vasculopathy.

An application of astragalus polyose in preparing the medicines for preventing and treating the insulin resistant diseases, such as diabetes, obesity, diabetic hematangionosus, diabetic hepatism, etc, is disclosed.

The invention discloses an alprostadil liposome composite medicine, which is a composite medicine comprising the main ingredients, i.e., high-purity alprostadil liposome and a mixture of Aspisol and soldium salicylate with the weight ratio of (85-95): (5-15), and discloses the weight ratio of the raw materials of the ingredients in the composite medicine; the invention further provides a preparation method and quality control of the alprostadil liposome composite medicine; a freeze-dried injection, or an oral preparation, or a spraying agent, or a suppository or an enema of the alprostadil liposome composite medicine is prepared; the chromatographic conditions of the contents of the alprostadil, the prostaglandin A1 and the prostaglandin B1 are measured, and three retention peaks before and after the alprostadil retention peak are the characteristic retention peaks of the supplementary materials of the alprostadil liposome composite medicine provided by the invention; the alprostadil liposome composite medicine is used for treating and preventing the diseases such as coronary heart disease and myocardial infarction, cerebral infarction, hypertension, hyperlipidemia, arteriosclerosis, vasculitis, tumor, hepatitis, aiabetic angiopathy and renal insufficiency, bronchial asthma, pancreatitis, gastric ulcer and vertebrobasilar insufficiency and the like.

An establishment method of a diabetic vasculopathy model based on a microfluidic chip is especially directed at vascular wall adhesiveness characteristic variation resulted from vascular endothelial inflammation in diabetic vasculopathy process, and phenomena of adhesion and rolling of mononuclear cells on surfaces of endothelial cells, thrombosis and vascular obstruction under simulation of blood flow conditions. The microfluidic chip is composed of a cell inlet pool (1), a cell culture chamber (2) and an outlet pool (3), wherein the upper of the cell culture chamber (2) is connected with the cell inlet pool (1), and the lower of the cell culture chamber (2) is connected with the outlet pool (3). The establishment method can integrate vasculopathy simulation under the condition of high blood sugar and interaction studies of mononuclear cells and lesion endothelial cell surfaces under the blood flow conditions in one, and can simultaneously realize simulation of the lesion site and in-situ simulation of thrombosis in complications of diabetes.

The invention relates to an alprostadil composite medicine comprising high-purity alprostadil and a mixture of aspirin-DL-lysine and sodium salicylate, wherein a weight ratio of aspirin-DL-lysine to sodium salicylate is 90-95:5-10. The invention also provides a weight ratio of the raw materials of the composite medicine. The invention also provides a preparation method of the alprostadil composite medicine, and a quality controlling method of the alprostadil composite medicine. With a pharmaceutically acceptable alprostadil composite medicine dosage, the medicine can be prepared into lyophilized injections, oral preparations, aerosols, suppositories, or enemas of the acceptable alprostadil composite medicine. The invention discloses chromatographic conditions for determining the contents of alprostadil, prostaglandin A1 and prostaglandin B1. Three peaks before an alprostadil peak are characteristic peaks of alprostadil composite medicine auxiliary materials. The alprostadil composite medicine is used for treating and preventing diseases such as coronary heart disease, myocardial infarction, brain infarction, hypertension, hyperlipemia, atherosclerosis, angiitis, tumour, hepatitis, diabetic angiopathies, kidney insufficiency, bronchial asthma, pancreatitis, gastric ulcer, and vertebrobasilar insufficiency.

The invention discloses application of brazilin in preparation of products for prevention, mitigation and / or treatment of diseases related to protein tyrosine kinase activity abnormal increase and vascular proliferation. Brazilin has the effects of inhibiting protein tyrosine kinase (PTKs) activity and inhibiting proliferation and migration of the rat thoracic aortic vascular smooth muscle cell (VSMC). Brazilin can prevent, mitigate and / or treat PTKs activity abnormal increase related diseases like tumors, restenosis after percutaneous coronary intervention (PCI), atherosclerosis, high blood pressure, multiple sclerosis, diabetic retinopathy, endometriosis, psoriasis and other skin diseases, asthma and other diseases. Brazilin can prevent, mitigate and / or treat vascular proliferation related diseases like restenosis after PCI, atherosclerosis, high blood pressure, neointima formation after vascular transplantation, vascular diseases after organ transplantation, diabetic angiopathies and the like.

The invention relates to a medicine composition composed of one of a pharmaceutically acceptable dose of alpha-glucosidase inhibitor and active metabolite of salt thereof, one or more of pharmaceutically acceptable doses of vitamin B, and a pharmaceutically acceptable carrier. The invention belongs to the field of medicine. The invention also relates to an application of the composition in preparing diabetes-treating medicines. With a medicine prepared by using the medicine composition provided by the invention, blood sugar can be effectively reduced, and a beneficial effect of substantially controlling diabetes vascular lesion complications is provided. Therefore, the medicine is a more appropriate anti-diabetic medicine.

The invention discloses a couplet medicine extract which is prepared by extracting radix rehmanniae and dogwood according to the weight ratio of 2:1. The preparation method of the couplet medicine extract comprises the following steps of: (1) weighing radix rehmanniae and dogwood, evenly mixing according to the weight ratio of 2:1, extracting for 2-3 times (1-2 hours every time) with distilled water of which the weight is 8-12 times of the weight of the medicinal materials; and (2) filtering the couplet medicine water extract with gauze, centrifuging the filtered solution, mixing the supernatant solutions, evaporating and concentrating in a rotating way, drying by distillation in a water bath, and drying under the reduced pressure to the constant weight to obtain the couplet medicine extract. The yield of the extract is 71.9%, and the content of total iridoid glycoside in the extract is 12.48%. The pharmacological test result shows that the extract has the functions of reducing sugar content, protecting blood vessels and improving the levels of the internal and external factors of the blood vessels, and has a unique function of protecting the kidney and heart. Thus, the couplet medicine extract provided by the invention can be used for preparing medicaments for reducing sugar content and preventing diabetic angiopathy.

The invention discloses a traditional Chinese medicinal composition for strengthening spleen and activating collaterals and an application thereof. The formula comprises the following components in parts by weight: 15-25 parts of radix puerariae, 12-18 parts of radix salviae miltiorrhizae, 25-35 parts of rhizoma atractylodis macrocephalae, 25-35 parts of radix codonopsis, 8-12 parts of cortex phellodendri, 8-12 parts of rhizoma acori graminei, 12-18 parts of pheretima, 8-12 parts of ligusticum wallichii, 25-35 parts of radix astragali and 8-12 parts of radix notoginseng. The traditional Chinese medicinal composition is a prescription for treating diabetes from treatise on the spleen and stomach, has the functions of strengthening spleen and supplementing qi, and promoting blood circulationto remove meridian obstruction, is used for treating diabetes caused by spleen deficiency and collateral stasis, with the symptoms, such as polydipsia, polyuria and polyphagia due to dry mouth, fatigue and asthenia, sallow or darkish complexion, abdominal fullness and distention, poor appetite, squamous and dry skin, limb paralysis and pain, dominated stabbing pain, aggravated pain at night, intermittent claudication, hemiplegia, distortion of commissure, pale and dingy tongue with bruises, white tongue fur, deep, thin and astringent pulses and the like, and has an obvious curative effect after being taken by patients with the syndromes, such as diabetes and diabetic peripheral neuropathy, diabetic angiopathy, diabetic retinopathy, diabetes complicated with a coronary heart disease and diabetes complicated with cerebral infarction.

The invention discloses a composition capable of promoting blood circulation to remove blood stasis, dredging collaterals and lowering lipid. The composition is prepared by, by weight, 6-21 parts of salviae miltiorrhizae, 3-15 parts of rhizoma chuanxiong, 3-18 parts of pseudo-ginseng, 3-21 parts of fructus crataegi, 2-15 parts of carthamus tinctorius and 2-18 parts of American ginseng. The composition has effects of lowering lipid and eliminating turbidity, promoting blood circulation and dredging collaterals, tonifying qi and promoting blood circulation to remove blood stasis, is evident in curative effect, quick in action, clearly and widely applicable to the treatment of diseases such as hypertension, coronary heart disease, diabetic blood vessel diseases and high blood viscosity, highin cure rate, free of toxic and side effects, free of untoward effect, capable of avoiding relapse, safe and convenient and capable of comprehensively regulating lipid, and has a practical applicationand popularization value.

The invention relates to application of a treatment effective dose of goniolactones C, a medicine composition with the goniolactones C, a medicine box with the goniolactones C and / or an apparatus such as a strut with the goniolactones C and a method for treating or preventing disease states by means of suppressing proliferation and / or migration of smooth muscle cells. Diseases can be selectively blood vessel wall thickening and narrow vessel lumen type cardiovascular and cerebrovascular diseases due to endothelial injury, proliferation of the vascular smooth muscle cells and deposition of matrixes and include diseases due to atherosclerosis, restenosis after angioplasty, hypertension, pulmonary hypertension and diabetic angiopathies.

The present invention belongs to the field of Chinese medicine, and is especially compound medicine preparation for treating diabetes and its preparation process. The present invention prepares the compound medicine preparation with Chinese medicine material Chinese goldthread, rhubarb and cassia as main material and through compounding with supplementary material, alcohol soaking, reflux extraction, drying and crushing, mixing with superfine Chinese goldthread and cassia powder, tabletting, and coating. Animal experiment and clinical application show that the compound medicine preparation can reduce blood sugar while reducing blood fat, delaying pathological changes of blood vessel caused by diabetes, and producing no any toxic side effect.

The invention belongs to the field of biomedicine and relates to application of micromolecule RNA (Ribonucleic Acid) in preparing a medicament, in particular to action of miR-145 for treating inflammatory metabolic diseases including diabetes. Proved by a test, in the invention, under the conditions of high glucose and high fat, micro RNA participates in generation and development of inflammationlesions of metabolic diseases including diabetic vascular lesions and can be used for preparing a medicament for treating inflammation, in particular to preparing a medicament for treating the inflammatory metabolic diseases including the diabetes and a preparation for detecting the diabetes. The miR-145 can be used as a detection index of a diabetics and as a treatment target spot of inflammatory diseases including diabetic macroangiopathy.

The invention provides an effective medicine part compatibility composition for preventing and treating diabetics and vascular diseases of diabetics. The effective medicine part compatibility composition is prepared from the following effective parts of rehmannia glutinosa and dogwood in weight proportions: 2-3 parts of total iridoid glycoside extract of rehmannia glutinosa, 3-5 parts of total iridoid glycoside of dogwood and, 0.5-1.5 parts of total triterpenes acid extract of dogwood. The research result of an STZ-induced C57BL / 6 mouse diabetic model shows that the composition can remarkably improve the symptoms of 'three excessiveness and one insufficiency' of a diabetic mouse, can reduce the blood sugar value, can improve secretion of insulin, can reduce serum creatinine, urea nitrogen and AGEs levels, can improve discharge of urine creatinine, can reduce discharge of urine protein, and can improve pathological change of pancreas, kidneys, testis and hearts. The composition has the function of reducing blood sugar and ascular diseases of diabetics.

The invention relates to a pharmaceutical composition containing glinide hypoglycemic medicines (glinides for short) and vitamin B, and use of the pharmaceutical composition. The pharmaceutical composition is prepared from one of therapeutically effective amounts of glinides and a medicinal precursor thereof, active metabolites or salts, one or more of therapeutically effective amounts of vitamins B, and pharmaceutically acceptable carriers, wherein the glinides mainly comprise repaglinide, nateglinide and mitiglinide; the content of the glinides is 0.5-120mg; the content of the vitamins B is 0.01-50mg. The invention also relates to use of the composition in preparation of a medicament for treating diabetes mellitus. The medicament prepared from the pharmaceutical composition provided by the invention has a more significant effect of preventing or delaying diabetes vascular lesion complications on the basis of effectively reducing blood sugar. In addition, a sufferer can be convenient to take medicine, and the compliance can be increased.

The invention relates to a novel coumarin glycoside compound derived from esculine or skimmin and a synthesis method thereof, and application of the novel coumarin glycoside compound and 7-O-methylesculine as drugs in diseases related to diabetic angiopathies. The in-vitro activity evaluation shows that the compound has obvious free radical removal action and ADP (adenosine diphosphate)-induced platelet aggregation inhibition action. The overall animal drug effect evaluation experiment result indicates that the 7-O-methylesculine can resist experimental hyperlipemia and inhibit atherosclerosis from formation, has obvious higher activity than esculine, and has application prospects in the aspect of resisting diseases related to diabetic angiopathies.

The invention discloses application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy. The application of the loureirin A to the preparation of the medicine forpreventing or treating the diabetic angiopathy is provided based on the fact that the inventor finds for the first time that the loureirin A has an obvious curative effect on the diabetic angiopathy caused by vascular endothelial injury caused by methylglyoxal. The methylglyoxal is a highly active glucose toxic metabolite, and is greatly increased in patients with diabetes, especially in patientswith complications of the diabetes. The curative effect of the loureirin A on the diabetic angiopathy caused by the vascular endothelial injury caused by the methylglyoxal is specifically reflected inimproving cell morphology, increasing the cell survival rate, reducing the apoptosis rate, alleviating cell oxidative stress injury, removing the methylglyoxal and reducing the content of advanced glycosylation end products and the like.

The invention relates to medical application of N6022 in treating diabetic peripheral arterial diseases, and relates to the cardiovascular field. At an animal level, in a diabetic mouse side limb ischemia model, by means of tail vein injection of N6022, blood flow recovery can be improved, angiogenesis of skeletal muscles can be improved, and the diabetic peripheral arterial diseases can be alleviated. At a cell level, by giving a GSNOR inhibitor, N6022 can alleviate reduction, caused by high glucose, of the human umbilical vein endothelial cell (HUVEC) migration capacity and vessel formationcapacity. A new application field of N6002 is exploited, and a meaningful reference is provided for treating the diabetic peripheral arterial diseases and improving diabetic vascular lesion conditions.

The invention provides berberine and panax notoginseng saponins and use of a composition using berberine and panax notoginseng saponins as effective components in preparing medicines for preventing and treating diabetes mellitus and complications thereof. The complications of diabetes mellitus are selected from diabetic cardiac abnormalities, diabetic renal lesions, diabetic retinopathy, diabetic peripheral neuropathy and diabetic vasculopathy.

The invention discloses a medicine for treating diabetic angiopathy. The medicine comprises an orally taken medicine and an externally applied medicine; the orally taken medicine comprises Radix Ginseng, Bulbus Lilii, Rhizoma disporopsis pernyi, Ganoderma Lucidum Karst, Thallus Porphyrae, Radix Codonopsis lanceolatae, Herba Urariae crinitae, Radix Oenotherae erythrosepalae oil, Radix Tiliae, Plantula Brassicae chinensis, Folium Ilicis Cornutae and Radix Glycyrrhizae; and the externally applied medicine comprises Radix Angelicae Sinensis, Radix Ginseng, Ganoderma Lucidum Karst, Fructus syzygii cumini, Fructus Lycii and Radix Glycyrrhizae. The medicine has the beneficial effect that the medicine comprises the orally taken medicine and the externally applied medicine, the orally taken medicine and the externally applied medicine are used jointly and interwork, the medicine takes effect quickly and is good in effect when used for clinically treating diabetic retinopathy caused by deficiency of both Qi and Yin, eye pressure can be relieved effectively, retinal neovascularization is reduced effectively, vision of a patient is improved, living quality of the patient is improved, meanwhile, the medicine is high in safety and does not have toxic or side effects, and the disease is difficult to recur.

The inventin discloses a short peptide, which has the effect of relieving necrocytosis, cell apoptosis and / or cell hypertrophy caused by hyperglycemia and recovering the proliferation effect of isletcells due to diabetes; therefore, by dosing a patient suffered from diabetes or hyperglycemia with the peptide in the invention, the function of effectively treating the diabetes or complications thereof; wherein, the diabetes complications may include diabetic cardiopathy, diabetic vasculopathy, diabetic hepatic pathological changes, diabetic nephropathy, pancreatic necrosis, etc.

The invention discloses the application of dragon blood A in the preparation of drugs for preventing or treating diabetic vascular disease. The present invention is based on the invention that the inventors of the present invention firstly found that dragon blood A has obvious curative effect on diabetic vascular disease caused by vascular endothelial injury caused by methylglyoxal. Methylglyoxal is a highly active glucose-toxic metabolite, which is greatly increased in diabetic patients, especially in patients with diabetic complications. The curative effect of dragon blood element A on diabetic vascular disease caused by endothelial injury caused by methylglyoxal is embodied in improving cell morphology, increasing cell survival rate, reducing cell apoptosis rate, alleviating cell oxidative stress damage, clearing methylglyoxal and reducing sugar residues. Chemical end product content and so on.

The invention relates to application of a treatment effective dose of goniolactones C, a medicine composition with the goniolactones C, a medicine box with the goniolactones C and / or an apparatus such as a strut with the goniolactones C and a method for treating or preventing disease states by means of suppressing proliferation and / or migration of smooth muscle cells. Diseases can be selectively blood vessel wall thickening and narrow vessel lumen type cardiovascular and cerebrovascular diseases due to endothelial injury, proliferation of the vascular smooth muscle cells and deposition of matrixes and include diseases due to atherosclerosis, restenosis after angioplasty, hypertension, pulmonary hypertension and diabetic angiopathies.